Median Technologies

Equities

ALMDT

FR0011049824

Advanced Medical Equipment & Technology

Real-time Euronext Paris Other stock markets 11:06:04 2024-04-26 am EDT			5-day change	1st Jan Change
3.05 ^EUR	-7.58%		-11.47%	-35.79%

2023	European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche	MT
2023	Median: final tranche of EIB loan approved	CF

Median Technologies SA Announces Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2021

January 17, 2022 at 11:45 am EST

Median Technologies SA announces revenue results for the fourth quarter and full year ended December 31, 2021. The company recorded €5.1 million in revenue in fourth quarter 2021, a 24.4% increase compared to fourth quarter revenue in 2020 (€4.1 million).

As of December 31, 2021, revenue was €20.5 million, a 52% increase compared to 2020 revenue.

Latest news about Median Technologies

European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche	Dec. 28	MT
Median: final tranche of EIB loan approved	Dec. 27	CF
Median: an alliance in cancer biomarkers	Dec. 15	CF
Median Technologies and Pasrel-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine	Dec. 14	CI
Median: diagnostics portfolio renamed 'eyonis	Nov. 27	CF
Median Technologies Rebrands Software-as-Medical-Devices Business as Eyonis	Nov. 27	MT
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-18	CI
Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress	23-10-17	CI
Median Technologies: appointment to the Board of Directors	23-10-11	CF
Median Technologies Appoints Ben Mcdonald to Its Board of Directors	23-10-10	CI
Median Technologies SA(ENXTPA:ALMDT) dropped from S&P Global BMI Index	23-09-18	CI
Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD	23-07-17	CI
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Median Technologies SA announced that it expects to receive â‚¬10 million in funding from Lake Bridge Capital Inc	23-07-11	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies to Present New and Breakthrough Results for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-28	CI
Global markets live: Adecco, Bayer, Chevron, Target, Tesla...	23-02-28
Median: preliminary submissions phase finalized in the USA	23-02-28	CF
Median Technologies Announces Completion of the Q-Submission Phase with the FDA for Its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-27	CI
Median Technologies SA Announces Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-01-19	CI
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-20	CI
Median Technologies Sa Reports Revenue Results for the Third Quarter and First Three Quarters Ended September 30, 2022	22-10-20	CI
Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening	22-10-03	CI
Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials	22-05-31	CI

Chart Median Technologies

Duration

Period

More charts

Company Profile

Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «iBiopsy», its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care. Provision of services accounts for all net sales. Net sales are distributed geographically as follows: France (4%), the United States and Canada (37%), China (19.2%), the United Kingdom (18.9%) and other (20.9%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Median Technologies

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.3 EUR

Average target price

24.4 EUR

Spread / Average Target

+639.39%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
MEDIAN TECHNOLOGIES	-35.79%	64.96M
THERMO FISHER SCIENTIFIC	+7.91%	218B
DANAHER CORPORATION	+6.11%	182B
INTUITIVE SURGICAL, INC.	+11.73%	132B
BOSTON SCIENTIFIC CORPORATION	+26.80%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.83%	52.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.59B
AGILENT TECHNOLOGIES, INC.	-0.81%	39.96B
GE HEALTHCARE TECHNOLOGIES INC.	+11.15%	39.22B
RESMED, INC.	+25.32%	26.94B

Other Advanced Medical Equipment & Technology